We found that drugs on the extreme ends, such as Selumetinib (ρ=0.2965, q=0.0449), a MEK inhibitor (MAP2K1), KB-R7943 (ρ=0.2977, q=0.0476), a sodium/calcium exchange inhibitor (SLC8A1), and Nefiracetam (ρ=0.3034, q=0.0273), an acetylcholine receptor agonist and GABA receptor agonist (CHRM1) to express reverse signatures to the AD group for sPC4 (Figure 6C). The gene discussed is MAP2K1; the disease is Alzheimer disease.